BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 27046135)

  • 1. Central nervous system involvement in T-cell lymphoma: A single center experience.
    Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
    Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma.
    Chihara D; Fanale MA; Miranda RN; Noorani M; Westin JR; Nastoupil LJ; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Turturro F; Lee HJ; Neelapu SS; Rodriguez MA; Wang M; Fowler NH; Davis RE; Medeiros LJ; Oki Y
    PLoS One; 2018; 13(3):e0191461. PubMed ID: 29538376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
    Sancho JM; Ribera JM; Oriol A; Hernandez-Rivas JM; Rivas C; Bethencourt C; Parody R; Deben G; Bello JL; Feliu E;
    Cancer; 2006 Jun; 106(12):2540-6. PubMed ID: 16700036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
    Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
    Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
    Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R; Goy A; Castillo JJ; Jagadeesh D; Woda B; Rosen ST; Smith SM; Evens AM
    Ann Oncol; 2014 Nov; 25(11):2211-2217. PubMed ID: 25193992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
    Arkenau HT; Chong G; Cunningham D; Watkins D; Agarwal R; Sirohi B; Trumper M; Norman A; Wotherspoon A; Horwich A
    Ann Oncol; 2007 Mar; 18(3):541-5. PubMed ID: 17164228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
    Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
    Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
    Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
    Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Liposomal cytarabine in prophylaxis of the central nervous system involvement in rare aggresive lymphomas].
    Kumiega B; Jurczak W; Fornagiel S; Dzietczenia J; Skotnicki AB
    Przegl Lek; 2013; 70(4):187-90. PubMed ID: 23991555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.
    Jurczak W; Kroll-Balcerzak R; Giebel S; Machaczka M; Giza A; Ogórka T; Fornagiel S; Rybka J; Wróbel T; Kumiega B; Skotnicki AB; Komarnicki M
    Med Oncol; 2015 Apr; 32(4):90. PubMed ID: 25716885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry.
    Wudhikarn K; Bunworasate U; Julamanee J; Lekhakula A; Chuncharunee S; Niparuck P; Ekwattanakit S; Khuhapinant A; Norasetthada L; Nawarawong W; Makruasi N; Kanitsap N; Sirijerachai C; Chansung K; Wong P; Numbenjapon T; Prayongratana K; Suwanban T; Wongkhantee S; Praditsuktavorn P; Intragumtornchai T;
    Ann Hematol; 2017 Jan; 96(1):57-64. PubMed ID: 27752821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
    Kansara R
    Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.
    González-Barca E; Canales M; Salar A; Ferreiro-Martínez JJ; Ferrer-Bordes S; García-Marco JA; Sánchez-Blanco JJ; García-Frade J; Peñalver J; Bello-López JL; Sancho JM; Caballero D;
    Ann Hematol; 2016 May; 95(6):893-9. PubMed ID: 27025508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central nervous system involvement in diffuse large B-cell lymphoma.
    Yamamoto W; Tomita N; Watanabe R; Hattori Y; Nakajima Y; Hyo R; Hashimoto C; Motomura S; Ishigatsubo Y
    Eur J Haematol; 2010 Jul; 85(1):6-10. PubMed ID: 20236301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central nervous system prophylaxis in diffuse large B-cell lymphoma.
    Zahid MF; Khan N; Hashmi SK; Kizilbash SH; Barta SK
    Eur J Haematol; 2016 Aug; 97(2):108-20. PubMed ID: 27096423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.
    Cheah CY; Herbert KE; O'Rourke K; Kennedy GA; George A; Fedele PL; Gilbertson M; Tan SY; Ritchie DS; Opat SS; Prince HM; Dickinson M; Burbury K; Wolf M; Januszewicz EH; Tam CS; Westerman DA; Carney DA; Harrison SJ; Seymour JF
    Br J Cancer; 2014 Sep; 111(6):1072-9. PubMed ID: 25072255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
    Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP
    Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma.
    Puckrin R; El Darsa H; Ghosh S; Peters A; Owen C; Stewart D
    Am J Hematol; 2021 Jul; 96(7):764-771. PubMed ID: 33811794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.
    Savage KJ; Chhanabhai M; Gascoyne RD; Connors JM
    Ann Oncol; 2004 Oct; 15(10):1467-75. PubMed ID: 15367405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.